Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brendan L. Mangan"'
Autor:
Brendan L. Mangan, Dilan Patel, Heidi Chen, Katie S. Gatwood, Michael T. Byrne, Salyka Sengsayadeth, Stacey Goodman, Bhagirathbhai Dholaria, Adetola A. Kassim, Madan Jagasia, Wichai Chinratanalab, Kathryn A. Culos, Brian G. Engelhardt
Publikováno v:
eJHaem, Vol 1, Iss 2, Pp 576-580 (2020)
Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diab
Externí odkaz:
https://doaj.org/article/c10492381e0a4e2f84e708a1430bb2ac
Autor:
Molly E. Graveno, Alison Carulli, Craig W. Freyer, Brendan L. Mangan, Robert Nietupski, Alison W. Loren, Noelle V. Frey, David L. Porter, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Daria V. Babushok, Keith W. Pratz
Publikováno v:
Leukemia & Lymphoma. 63:1645-1650
Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve
Autor:
Kathryn A. Culos, Madan Jagasia, Heidi Chen, Adetola A. Kassim, Wichai Chinratanalab, Katie S. Gatwood, Salyka Sengsayadeth, Brendan L. Mangan, Brian G. Engelhardt, Bhagirathbhai Dholaria, Stacey Goodman, Dilan A Patel, Michael Byrne
Publikováno v:
EJHaem
Haploidentical hematopoietic cell transplant (haplo-HCT) with post-transplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new-onset post-transplant diabetes mellitus (P
Autor:
Kathryn A. Culos, Michael Byrne, Lindsay Orton, Tae Kon Kim, Heidi Chen, Katie S. Gatwood, Adetola A. Kassim, Brendan L. Mangan, Bipin N. Savani, Bhagirathbhai Dholaria, Reena Jayani, Brian G. Engelhardt
Publikováno v:
Transplantation and Cellular Therapy. 27:S143-S144
Autor:
Bipin N. Savani, Katie S. Gatwood, Madan Jagasia, Stacey Goodman, Brendan L. Mangan, Adetola A. Kassim, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Dilan A Patel, Wichai Chinratanalab, Heidi Chen, Kathryn A. Culos, Robert F. Cornell, Michael Byrne, Brian G. Engelhardt
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S354-S355
The mortality rate triples for the 50% of patients diagnosed with new-onset post-transplant diabetes mellitus (PTDM) after HLA-identical allogeneic hematopoietic cell transplant (HCT) (Griffith, BBMT 2011). Haploidentical HCT (haplo-HCT) with post-tr
Autor:
Javid Moslehi, Douglas B. Johnson, Renee K. McAlister, Andrew Gibson, Elizabeth J. Phillips, Brendan L. Mangan, Justin M. Balko
Publikováno v:
Br J Clin Pharmacol
Immune checkpoint inhibitors have emerged as a revolutionary treatment option for patients with various types of malignancy. Although these agents afford a significant improvement in outcomes for melanoma and other previously untreatable malignancies